NASDAQ: KRROKorro Bio Inc Stock
$58.53-4.46 (-7.08%)
Updated Apr 25, 2024
KRRO Price
$58.53
Fair Value Price
$86.93
Market Cap
$469.52M
52 Week Low
$9.15
52 Week High
$97.91
P/E
-1.1x
P/B
2.76x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$81.17M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.31
Operating Cash Flow
-$67M
Beta
0.97
Next Earnings
Jun 11, 2024
Ex-Dividend
N/A
Next Dividend
N/A
KRRO Overview
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KRRO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KRRO ($58.53) is undervalued by 32.67% relative to our estimate of its Fair Value price of $86.93 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
KRRO ($58.53) is significantly undervalued by 32.67% relative to our estimate of its Fair Value price of $86.93 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
KRRO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KRRO due diligence checks available for Premium users.
Be the first to know about important KRRO news, forecast changes, insider trades & much more!
KRRO News
Valuation
KRRO fair value
Fair Value of KRRO stock based on Discounted Cash Flow (DCF)
Price
$58.53
Fair Value
$86.93
Undervalued by
32.67%
KRRO ($58.53) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KRRO ($58.53) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KRRO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KRRO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.1x
Industry
15.41x
Market
40.97x
KRRO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.76x
Industry
5.8x
KRRO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KRRO's financial health
Profit margin
Revenue
$0.0
Net Income
-$39.2M
Profit Margin
0%
KRRO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$221.7M
Liabilities
$51.8M
Debt to equity
0.31
KRRO's short-term assets ($172.73M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KRRO's short-term assets ($172.73M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KRRO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
KRRO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$39.9M
Investing
-$20.4M
Financing
$201.9M
KRRO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KRRO vs Biotech Stocks
Korro Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.